Fundraise

Marrow debuts with $120M Series B to target blood disorders in vivo

What's the deal? Marrow TherapeuticsDealroom has a profile for this one. Try Dealroom → launched with $173 million in combined financing to develop genetic medicines for severe blood disorders. OrbiMed led the $120 million Series B, with participation from RTW InvestmentsDealroom has a profile for this one. Try Dealroom →, KKR, Columbia Threadneedle InvestmentsDealroom has a profile for this one. Try Dealroom → and other new backers, while founder Scion Life SciencesDealroom has a profile for this one. Try Dealroom → and venBio co-led a $53 million Series A. The Watertown, Massachusetts-based biotech will fund its bone marrow-targeted platform.

What's the endgame? Marrow's Transferrin Antibody Bioconjugate technology aims to deliver therapeutic payloads straight to bone marrow cells, bypassing the safety, manufacturing, and accessibility limits of traditional genetic medicines. Its lead candidate, MAR-101, is preclinical and designed to treat sickle cell disease and beta thalassemia by reducing the BCL11a gene and reactivating fetal haemoglobin production.

Why now? Approved ex vivo therapies — Vertex and CRISPR's Casgevy and GenetixDealroom has a profile for this one. Try Dealroom →'s Lyfgenia — validated genetic modification for these diseases in late 2023. But both demand intensive administration, and Lyfgenia carries a boxed warning for blood cancers with lifelong monitoring.

Who's running it? Chief executive officer Romesh Subramanian, a Scion venture partner with over 20 years of industry experience, leads the company. He is joined by chief scientific officer Tim Weeden and chief operating and technology officer John Najim, both from Dyne Therapeutics.

"We're at a pivotal moment in genetic medicine and its application in severe blood disorders—the field has validated key targets and shown that genetic approaches can work, but we need to solve the safety and accessibility challenges," Subramanian said.

What could go wrong? MAR-101 remains preclinical, so Marrow's claim to offer a safer, more scalable alternative is unproven. The financing signals investor appetite, not clinical validation.

The signal: Marrow's $120 million Series B ranks in the 95th percentile among US health Series B rounds, reflecting momentum behind in vivo approaches. Novartis recently agreed to pay Precision BioSciences $75 million upfront, plus up to $1.4 billion in milestones, for an in vivo sickle-cell gene-editing program, and the National Heart, Lung, and Blood Institute has launched its own effort — a sign the field is racing past the access hurdles of first-generation therapies.

Read more: biospace.com · businesswire.com · biopharmadive.com

Image credit: Marrow Therapeutics

More top stories